Bromuro de glicopirronio | Annual Sales Report | Pharmacompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Bromuro De Glicopirronio
Annual Reports

PharmaCompass Sponsored Ads

Contact Supplier

Glycopyrrolate

Contact Supplier

Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

Contact Supplier

Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Contact Supplier

Bromuro de glicopirronio

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

63 API Suppliers, 22 USDMF, 9 CEP/COS, 2 JDMF, 6 EU WC, 8 KDMF, 21 NDC API, 36 Listed Suppliers, $ API Reference Price

63 API Suppliers
22 USDMF
9 CEP/COS
2 JDMF
6 EU WC
8 KDMF
21 NDC API
36 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

98 Drugs in Development

98 Drugs in Development

FINISHED DOSAGE FORMULATIONS

197 FDF Dossiers, 88 FDA Orange Book, 68 Europe, 13 Canada, 2 Australia, 7 South Africa, 19 Listed Dossiers

197 FDF Dossiers
88 FDA Orange Book
68 Europe
13 Canada
2 Australia
7 South Africa
19 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 1MG, TABLET;ORAL - 2MG, INJECTABLE;INJECTION - 0.2MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, POWDER;INHALATION - 15.6MCG/INH, POWDER;INHALATION - 15.6MCG/INH;27.5MCG/INH, SOLUTION;INHALATION - 25MCG/ML, TABLET, ORALLY DISINTEGRATING;ORAL - 1.7MG

TABLET;ORAL - 1MG
TABLET;ORAL - 2MG
INJECTABLE;INJECTION - 0.2MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
POWDER;INHALATION - 15.6MCG/INH
POWDER;INHALATION - 15.6MCG/INH;27.5MCG/INH
SOLUTION;INHALATION - 25MCG/ML
TABLET, ORALLY DISINTEGRATING;ORAL - 1.7MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 2 Rochem International Inc, 6 SPI Pharma, 1 DKSH, 4 Boai NKY Pharmaceuticals Ltd, 5 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 4 Kirsch Pharma, 8 Actylis, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 10 BASF, 1 CD Formulation, 6 DFE Pharma, 3 Finar, 5 Gangwal Chemicals, 1 Ideal Cures, 3 Ingredion Pharma Solutions, 16 Kerry, 2 Keval Exports, 12 Microlex e.U, 1 Nippon Fine Chemical, 2 Nitika Pharmaceutical Specialities, 1 Novo Excipients, 3 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 26 Roquette, 1 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 9 Sigachi Industries, 3 Silverline Chemicals, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

54 Fillers, Diluents & Binders, 27 Direct Compression, 21 Granulation, 20 Parenteral, 17 Disintegrants & Superdisintegrants, 15 Thickeners and Stabilizers, 14 Film Formers & Plasticizers, 13 Co-Processed Excipients, 12 Taste Masking, 11 Lubricants & Glidants, 10 Solubilizers, 9 Chewable & Orodispersible Aids, 8 Coating Systems & Additives, 7 Topical, 7 Controlled & Modified Release, 3 Emulsifying Agents, 1 Soft Gelatin, 1 API Stability Enhancers, 1 Surfactant & Foaming Agents, 1 Rheology Modifiers, 1 Dry Powder Inhalation

54 Fillers, Diluents & Binders
27 Direct Compression
21 Granulation
20 Parenteral
17 Disintegrants & Superdisintegrants
15 Thickeners and Stabilizers
14 Film Formers & Plasticizers
13 Co-Processed Excipients
12 Taste Masking
11 Lubricants & Glidants
10 Solubilizers
9 Chewable & Orodispersible Aids
8 Coating Systems & Additives
7 Topical
7 Controlled & Modified Release
3 Emulsifying Agents
1 Soft Gelatin
1 API Stability Enhancers
1 Surfactant & Foaming Agents
1 Rheology Modifiers
1 Dry Powder Inhalation

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 1 Stock Recap #PipelineProspector, 116 News #PharmaBuzz

1 Data Compilation #PharmaFlow
1 Stock Recap #PipelineProspector
116 News #PharmaBuzz

GLOBAL SALES INFORMATION

32 US Medicaid Prescriptions, 14 Regulatory FDF Prices, 59 Annual Reports

32 US Medicaid Prescriptions
14 Regulatory FDF Prices
59 Annual Reports

MARKET PLACE

24 APIs, 1 FDF Dossiers

24 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

31 US Patents, 19 Health Canada Patents

31 US Patents
19 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 21 Others

3 EDQM
21 Others

$ API Ref.Price (USD/KG) : 25,861 Xls

Filters

Reset all filters

Filters

FILTER :

filter Product Reset all filters

59 All

01 7Bevespi

02 6Breztri

03 4Cortiment

04 1Eohilia

05 2Lonhala Magnair

06 11Pulmicort

07 6Seebri Breezhaler

08 7Symbicort

09 5Uceris

10 1Uceris/Cortiment

11 6Ultibro Breezhaler

12 3Ultibro Group

Inke Glycopyrronium Bromide

List of Suppliers

Product Main Page

01

Brand Name : Uceris

Budesonide, Glycopyrronium, Formoterol Fumarate

Aus. Peptide Conference

Not Confirmed

Brand Name : Uceris

Aus. Peptide Conference

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Cosmo Pharmaceuticals

Budesonide, Glycopyrronium, Formoterol Fumarate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 6

2019 Revenue in Millions : 11

Growth (%) : -48

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Brand Name : Symbicort

Budesonide, Glycopyrronium, Formoterol Fumarate

Aus. Peptide Conference

Not Confirmed

Brand Name : Symbicort

Aus. Peptide Conference

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Budesonide, Glycopyrronium, Formoterol Fumarate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 0

2019 Revenue in Millions : 213

Growth (%) : -100

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Brand Name : Lonhala Magnair

Aus. Peptide Conference

Not Confirmed

Brand Name : Lonhala Magnair

Aus. Peptide Conference

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Dainippon Sumitomo

Glycopyrrolate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 22

2019 Revenue in Millions : 17

Growth (%) : 28

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Brand Name : Pulmicort

Budesonide, Glycopyrronium, Formoterol Fumarate

Aus. Peptide Conference

Not Confirmed

Brand Name : Pulmicort

Aus. Peptide Conference

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

AstraZeneca

Budesonide, Glycopyrronium, Formoterol Fumarate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 996

2019 Revenue in Millions : 1,466

Growth (%) : -32

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

Brand Name : Breztri

Budesonide, Glycopyrronium, Formoterol Fumarate

Aus. Peptide Conference

Not Confirmed

Brand Name : Breztri

Aus. Peptide Conference

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

AstraZeneca

Budesonide, Glycopyrronium, Formoterol Fumarate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 28

2019 Revenue in Millions : 2

Growth (%) : 1,300

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

Brand Name : Cortiment

Budesonide, Glycopyrronium, Formoterol Fumarate

Aus. Peptide Conference

Not Confirmed

Brand Name : Cortiment

Aus. Peptide Conference

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Cosmo Pharmaceuticals

Budesonide, Glycopyrronium, Formoterol Fumarate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 8

2019 Revenue in Millions : 5

Growth (%) : 70

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

Brand Name : Symbicort

Budesonide, Glycopyrronium, Formoterol Fumarate

Aus. Peptide Conference

Not Confirmed

Brand Name : Symbicort

Aus. Peptide Conference

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

AstraZeneca

Budesonide, Glycopyrronium, Formoterol Fumarate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 2,721

2019 Revenue in Millions : 2,495

Growth (%) : 9

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

Brand Name : Bevespi

Aus. Peptide Conference

Not Confirmed

Brand Name : Bevespi

Aus. Peptide Conference

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

AstraZeneca

Glycopyrrolate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 48

2019 Revenue in Millions : 42

Growth (%) : 14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

Brand Name : Breztri

Budesonide, Glycopyrronium, Formoterol Fumarate

Aus. Peptide Conference

Not Confirmed

Brand Name : Breztri

Aus. Peptide Conference

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

AstraZeneca

Budesonide, Glycopyrronium, Formoterol Fumarate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2021 Revenue in Millions : 203

2020 Revenue in Millions : 28

Growth (%) : 625

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

Brand Name : Uceris

Budesonide, Glycopyrronium, Formoterol Fumarate

Aus. Peptide Conference

Not Confirmed

Brand Name : Uceris

Aus. Peptide Conference

Not Confirmed

Post an Enquiry

Post an Enquiry

Digital Content

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Cosmo Pharmaceuticals

Budesonide, Glycopyrronium, Formoterol Fumarate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2021 Revenue in Millions : 4

2020 Revenue in Millions : 5

Growth (%) : -31

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2
3
Last

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!